NECLIFE — Nectar Lifesciences Share Price
0.000.00%
Last trade - 00:00- IN₹7.73bn
- IN₹14.20bn
- IN₹15.24bn
- 90
- 64
- 88
- 96
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.72 | ||
| Price to Tang. Book | 0.76 | ||
| Price to Free Cashflow | 5.24 | ||
| Price to Sales | 0.47 | ||
| EV to EBITDA | 11.67 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 4.84% | ||
| Return on Equity | 0.76% | ||
| Operating Margin | 3.73% | ||
Financial Summary
| Year End 31st Mar | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | 27,828.65 | 23,663.79 | 15,443.69 | 16,688.32 | 15,236.69 | n/a | n/a | -4.33% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -8.09 | -34.04 | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Nectar Lifesciences Limited is an India-based pharmaceutical company. The Company's business areas include active pharmaceutical ingredients (APIs) and intermediates, formulations/finished dosage formulations (FDF), menthol and mint derivatives, and empty hard gelatin capsules. The Company is engaged in the manufacturing of oral and sterile cephalosporin products. Its oral cephalosporins include cefixime, cefurozime axetil crystalline, cefuroxime axetil amorphous, cedpodoxime proxetil, cefprozil and cefdinir. Its sterile cephalosporins include cefotaxime sodium, ceftriaxone sodium, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate and cefepime arginine. Its capacities include cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium and ceftriaxone sodium. The Company offers contract manufacturing capabilities for solid dosage forms, such as tablets, capsules, dry powder oral suspension and granules and injectable for cephalosporins.
Directors
- Sanjiv Goyal CHM (52)
- Dinesh Dua CEO (56)
- Sandeep Goel CFO
- .. Anubha CCO
- Ankita Jain CCO
- Ravi Aggarwal VPR
- Harparkash Gill EDR (59)
- Aryan Goyal EDR (29)
- Vivek Sett NED (57)
- Kuldip Bhasin IND (71)
- Guljit Chaudhri IND
- Ajay Swaroop NID (63)
- Last Annual
- March 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- June 27th, 1995
- Public Since
- July 19th, 2005
- No. of Shareholders
- 64,058
- No. of Employees
- 1,589
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- National Stock Exchange of India
- Shares in Issue
- 224,260,970
- Address
- Sco 38-39,, Sector 9-D, CHANDIGARH, 160009
- Web
- https://www.neclife.com/
- Phone
- +91 1723047777
- Auditors
- Deepak Jindal & Co.
Upcoming Events for NECLIFE
Q1 2025 Nectar Lifesciences Ltd Earnings Release
Nectar Lifesciences Ltd Annual Shareholders Meeting
Similar to NECLIFE
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Drugs
National Stock Exchange of India
Aarti Pharmalabs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Accent Microcell
National Stock Exchange of India
FAQ
What is the Nectar Lifesciences share price?
As of Today at 19:15 UTC, shares in Nectar Lifesciences are trading at IN₹34.45. This share price information is delayed by 15 minutes.
How has the Nectar Lifesciences share price performed this year?
Shares in Nectar Lifesciences last closed at IN₹34.45 and the price had moved by +89.29% over the past 365 days. In terms of relative price strength the Nectar Lifesciences share price has outperformed the S&P BSE 100 Index by +47.05% over the past year.
What are the analyst and broker recommendations for Nectar Lifesciences?
The overall consensus recommendation for Nectar Lifesciences is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Nectar Lifesciences dividend yield?
Nectar Lifesciences does not currently pay a dividend.
Does Nectar Lifesciences pay a dividend?
Nectar Lifesciences does not currently pay a dividend.
When does Nectar Lifesciences next pay dividends?
Nectar Lifesciences does not currently pay a dividend.
How do I buy Nectar Lifesciences shares?
To buy shares in Nectar Lifesciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Nectar Lifesciences?
As of the previous close price of IN₹34.45, shares in Nectar Lifesciences had a market capitalisation of IN₹7.73bn.
Where are Nectar Lifesciences shares listed?
Here are the trading details for Nectar Lifesciences:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: NECLIFE
What kind of share is Nectar Lifesciences?
Based on an overall assessment of its quality, value and momentum Nectar Lifesciences is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Nectar Lifesciences share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Nectar Lifesciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Nectar Lifesciences. Over the past six months, its share price has outperformed the S&P BSE 100 Index by +24.14%.
As of the last closing price of IN₹34.45, shares in Nectar Lifesciences were trading +15.46% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Nectar Lifesciences PE Ratio?
The Nectar Lifesciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at IN₹34.45.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Nectar Lifesciences?
Nectar Lifesciences' management team is headed by:
- Sanjiv Goyal - CHM
- Dinesh Dua - CEO
- Sandeep Goel - CFO
- .. Anubha - CCO
- Ankita Jain - CCO
- Ravi Aggarwal - VPR
- Harparkash Gill - EDR
- Aryan Goyal - EDR
- Vivek Sett - NED
- Kuldip Bhasin - IND
- Guljit Chaudhri - IND
- Ajay Swaroop - NID